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Abstract
Introduction Manual interpretation of immunohistochemistry
(IHC) is a subjective, time-consuming and variable process, with
an inherent intra-observer and inter-observer variability.
Automated image analysis approaches offer the possibility of
developing rapid, uniform indicators of IHC staining. In the
present article we describe the development of a novel
approach for automatically quantifying oestrogen receptor (ER)
and progesterone receptor (PR) protein expression assessed by
IHC in primary breast cancer.
Methods Two cohorts of breast cancer patients (n = 743) were
used in the study. Digital images of breast cancer tissue
microarrays were captured using the Aperio ScanScope XT
slide scanner (Aperio Technologies, Vista, CA, USA). Image
analysis algorithms were developed using MatLab 7
(MathWorks, Apple Hill Drive, MA, USA). A fully automated
nuclear algorithm was developed to discriminate tumour from
normal tissue and to quantify ER and PR expression in both
cohorts. Random forest clustering was employed to identify
optimum thresholds for survival analysis.
Results The accuracy of the nuclear algorithm was initially
confirmed by a histopathologist, who validated the output in 18
representative images. In these 18 samples, an excellent
correlation was evident between the results obtained by manual
and automated analysis (Spearman's ρ = 0.9, P  < 0.001).
Optimum thresholds for survival analysis were identified using
random forest clustering. This revealed 7% positive tumour cells
as the optimum threshold for the ER and 5% positive tumour
cells for the PR. Moreover, a 7% cutoff level for the ER predicted
a better response to tamoxifen than the currently used 10%
threshold. Finally, linear regression was employed to
demonstrate a more homogeneous pattern of expression for the
ER (R = 0.860) than for the PR (R = 0.681).
Conclusions In summary, we present data on the automated
quantification of the ER and the PR in 743 primary breast
tumours using a novel unsupervised image analysis algorithm.
This novel approach provides a useful tool for the quantification
of biomarkers on tissue specimens, as well as for objective
identification of appropriate cutoff thresholds for biomarker
positivity. It also offers the potential to identify proteins with a
homogeneous pattern of expression.
Introduction
The oestrogen receptor (ER) remains the only reliable predic-
tor of endocrine responsiveness in breast cancer, and is argu-
ably the single most important predictive biomarker in clinical
oncology today [1]. Moreover, one of the most studied ER-reg-
ulated genes is the progesterone receptor (PR). Approxi-
mately 70% to 80% of all invasive breast cancers are ER-
positive and thus are considered likely to respond to endocrine
BCSS: breast cancer-specific survival; DAB: 3,3'-diaminobenzidine; ER: oestrogen receptor; HR: hazard ratio; IHC: immunohistochemistry; OS: over-
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therapy. The PR, which is positive in approximately 60% of
cases, may be even more important in predicting response to
anti-oestrogens [2].
Both premenopausal and postmenopausal women benefit
from 5 years of treatment with the anti-oestrogen tamoxifen
[3]. Current treatment guidelines for premenopausal women
with hormone-responsive breast cancer advocate a combina-
tion of ovarian ablation/suppression or chemotherapy, fol-
lowed by 5 years of tamoxifen treatment [4-6]. In hormone-
responsive postmenopausal women, data from large prospec-
tive randomised controlled trials involving aromatase inhibitors
are now emerging and herald new standards in adjuvant endo-
crine treatment [7,8]. The International Expert Consensus on
the Primary Therapy of Early Breast Cancer states that
tamoxifen may be an acceptable option, but that aromatase
inhibitors have shown superiority over tamoxifen in postmeno-
pausal breast cancer [5].
Irrespective of their menopausal status, arguably the single
most important issue for any breast cancer patient is the
assessment of her tumour hormone receptor status. The hor-
mone receptor status is routinely evaluated in all resected pri-
mary tumours to assess the levels of ER and PR.
Inmmunohistochemistry (IHC) performed on formalin-fixed tis-
sue sections is now the most commonly used assay, having
replaced biochemical-based methods. The hormone receptor
status is currently assessed by a pathologist; with a cutoff
threshold of 10% positive tumour cells being commonly
employed to predict responsiveness to adjuvant hormonal
therapy. Such a threshold can lead to significant intra-observer
variability. For example, one study of 172 German pathologists
highlighted the difficulties that can arise from manual assess-
ment, with 24% of ER staining interpreted as being falsely
negative [9]. Improved image analysis technologies have the
potential to circumvent the burden of interpretation and intra-
observer variability, offering the potential to develop objective
automated quantitative scoring models for IHC. A move away
from the semiquantitative manual scoring models currently
employed should lead to less variability in results, to increased
throughput and to the identification of new prognostic sub-
groups, which may not have been evident following initial man-
ual analysis alone [10].
In the present article we propose an automated approach,
based on unsupervised learning, to accurately assess the ER
and PR expression levels in an extensive cohort of breast can-
cer specimens. In particular, our approach employs a novel
approach to the identification of tumour nuclei, whereby non-
tumour structures, including stromal components and lym-
phocytic infiltrate, are automatically excluded from any
analysis. Such an approach should allow for more accurate
assessment of the IHC signal.
Materials and methods
Patients and tumour samples
Two patient cohorts were used in the present study (Table 1).
The studies were approved by the ethical committees at Lund
University and Linköping University.
Cohort I (test cohort) consisted of 179 consecutive cases of
invasive breast cancer diagnosed at the Department of Pathol-
ogy, Malmö University Hospital, Malmö, Sweden, between
2001 and 2002. The median age at diagnosis was 65 years
(range 35–97 years) and the median follow-up period for over-
all survival (OS) was 52 months (range 4–63 months).
Cohort II (validation cohort) consisted of 564 premenopausal
women with primary breast cancer from the south and south-
east regions of Sweden who enrolled in a multicentre clinical
trial between 1984 and 1991. Patients were randomly
assigned to either 2 years of adjuvant tamoxifen treatment (n
= 276) or to a control group (n = 288); the aim of this study
was to examine the effect of tamoxifen on recurrence-free sur-
vival (RFS) [2].
Tissue microarrays and immunohistochemistry
Tissue microarrays (TMAs) were constructed using either a
manual tissue arrayer (MTA-1; Beecher Inc., Sun Prairie, WI,
USA) (Cohort I) or an automated tissue arrayer (ATA-27;
Beecher Inc.) (Cohort II). Two 1.0 mm cores (Cohort I) or two
0.6 mm cores (Cohort II) were extracted from each donor
block and were assembled in a recipient block as previously
described [11]. IHC analysis was performed on 4 μm sections
in the Ventana Benchmark system (Ventana Medical Systems
Inc., Tucson, AZ, USA) using prediluted antibodies to the ER
(anti-ER, clone 6F11; Ventana) or to the PR (anti-PR, clone
16; Ventana) as previously described [11]. 3,3'-Diaminobenzi-
dine (DAB) was used as a chromogenic substrate, and the
slides were counterstained using haematoxylin.
Image acquisition, management and analysis
Digital images were captured using the Aperio ScanScope XT
Slide Scanner (Aperio Technologies, Vista, CA, USA) as pre-
viously described [10]. Figure 1a to 1f outline a schematic rep-
resentation of the algorithm output, and a full description is
available in Additional files 1 and 2.
Algorithm development and statistical analysis
Algorithms were developed using MatLab 7 (MathWorks,
Apple Hill Drive, MA, USA). Statistical analysis was carried out
using MatLab 7 (MathWorks) and SPSS version 11.0 (SPSS
Inc., Chicago, IL, USA). Spearman's ρ correlation was used to
estimate the relationship between automated and manual
analysis. Univariate Cox regression analysis, Kaplan–Meier
analysis and the log-rank test were used to illustrate differ-
ences between the RFS, OS and breast cancer-specific sur-
vival (BCSS) according to the expression of ER and PR. All PAvailable online http://breast-cancer-research.com/content/10/5/R89
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values are two-sided, and P < 0.05 was considered statisti-
cally significant.
Results
The present study involved the development of an automated
unsupervised nuclear algorithm to objectively assess the ER
and PR expression levels in 743 breast tumours. Two breast
cancer cohorts (n = 743) as described above were used
(Table 1). Manual ER and PR expression data were available
for 654 (88%) patients and 640 (86%) patients, respectively.
As a number of cores were not suitable for image analysis due
to large image artefacts, automated analysis was restricted to
639 patients (86%) for whom ER data were available and to
622 (84%) patients for whom PR data were available.
Quantitative assessment of ER and PR status: 
correlation between manual and automated approaches
Nuclear ER and PR expression levels were quantitatively
determined using the aforementioned algorithm (Figure 1a to
1f). The accuracy of the algorithm was confirmed by a his-
Table 1
Clinicopathological characteristics of Cohorts I and II
Cohort I (n = 179) Cohort II (n = 564)
Age (years)
Median (range) 65 (35 to 97) 45 (25 to 57)
Tumour size
≤ 20 mm 105 (59) 208 (37)
>20 mm 74 (41) 356 (63)
Grade
I 38 (21) 58 (10)
II 79 (44) 222 (40)
III 62 (35) 234 (42)
Missing 50 (8.9)
Histological type
Indeterminate 3 (2) 7 (2)
Invasive ductal carcinoma 125 (70) 411 (73)
Invasive lobular carcinoma 31 (17.3) 43 (7.6)
Tubular 16 (8.9) 5 (1)
Medullary 4 (2.2) 25 (4)
Mucinous 3 (1)
Missing 70 (12)
Nodal status
Negative 87 (49) 160 (28)
Positive 65 (36) 402 (71)
Missing 27 (15) 2 (0.3)
Oestrogen receptor status
Positive 157 (88) 324 (57)
Negative 22 (12) 151 (27)
Missing 89 (16)
Progesterone receptor status
Positive 52(29) 147 (26)
Negative 127 (71) 312 (55)
Missing 105 (19)
Data in parentheses represent percentages unless otherwise stated.Breast Cancer Research    Vol 10 No 5    Rexhepaj et al.
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topathologist (PH), who validated the output in 18 represent-
ative ER images. An excellent correlation was evident between
the percentage positive tumour nuclei as determined by image
analysis compared with determined by manual analysis
(Spearman's ρ = 0.9, P < 0.001) (Figure 1g). The estimated
misclassification rate of nuclei (tumour versus nontumour) was
< 10%, thus confirming the ability of the algorithm to identify
tumour from stromal tissue and also confirming the accuracy
of the algorithm in quantifying ER expression.
Following this initial validation stage, the ER and PR expres-
sion levels as determined by image analysis were compared
with the manual assessment of the two cohorts outlined
above. Figure 1h illustrates the distribution of ER expression
levels as determined by image analysis, and demonstrates a
Figure 1
Overview of the automated image analysis process and correlation between automated and manual analysis Overview of the automated image analysis process and correlation between automated and manual analysis. An example 500 × 500 pixel 
image taken to demonstrate the stepwise image process underlying the nuclear algorithm. (a) Original immunohistochemistry (IHC) section and (b) 
the equivalent H&E section. (c) Original IHC section after the extraction of 3,3'-diaminobenzidine (DAB)-positive tumour nuclei and (d) after the 
removal of DAB-negative tumour nuclei. (e) Identification (red) of DAB-positive tumour nuclei. (f) Identification (blue) of DAB-negative tumour nuclei. 
A more detailed description of the algorithm is available in Additional files 1 and 2. (g) Scatter plot demonstrating strong correlation between auto-
mated scores and manual annotation of the same cores by a pathologist. (h) Box plot (median, 25th and 75th quartiles) demonstrating the distribu-
tion of the oestrogen receptor (ER) quantitative automated data in relation to manual analysis in both cohorts. (i) Receiver-operator curves (ROCs) 
for the ER and the progesterone receptor (PR), with the number of false positives plotted along the abscissa and the number of true positives plot-
ted along the ordinate (a curve more to the upper-left corner implies better performance). (j) Heat map showing the correlation between ER and PR 
expression determined by both automated and manual analysis and a number of clinicopathological parameters.Available online http://breast-cancer-research.com/content/10/5/R89
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distinct separation between the ER-negative and the ER-posi-
tive groups in both cohorts. Similar results were evident for the
PR (data not shown). Once again, a strong correlation
between image analysis and manual assessment was evident
for both the ER (Spearman's ρ = 0.74, P < 0.001) and the PR
(Spearman's ρ = 0.62, P < 0.001). The algorithm was partic-
ularly impressive in borderline cases (that is, cases manually
annotated as 1% to 10% positive), where an accuracy level of
90% was evident. Receiver-operator curve analysis was also
performed comparing manually and automatically assessed
ER and PR expression levels (Figure 1i). The area under the
curve was excellent for both the ER (area under the curve =
0.85) and the PR (area under the curve = 0.74), further con-
firming the accuracy of the automated algorithm.
As breast cancer is a heterogeneous disease with different
histological subtypes and grades, the correlation between a
number of clinicopathological parameters and both manual
and automated assessment was examined. Figure 1j illustrates
that similar correlations were seen between the ER and PR
expression and histological subtypes, grade, tumour size and
a number of other IHC markers irrespective of the assessment
method employed (manual versus automated). Figure 1j dem-
onstrates a strong correlation between the ER and the PR,
whilst the ER and the PR are negatively associated with grade
irrespective of the type of assessment employed. No associa-
tion was evident between the ER or PR expression and histo-
logical subtype, suggesting that the automated approach is
not disrupted by the clinical heterogeneity of breast cancer.
To further validate the algorithm, the prognostic power of the
ER and PR expression as determined by image analysis was
compared with that derived from standard pathological
assessment. Cox univariate regression analysis was employed
to compare OS based on manual scores for the ER and the PR
versus OS obtained from automated analysis. Continuous
automated assessment of the ER and PR expression was
dichotomised using a threshold of 10%. Cox regression uni-
variate analysis was performed on both cohorts to assess the
difference in the RFS, OS and BCSS between ER-negative,
PR-negative (< 10%) samples and ER-positive, PR-positive
(>10%) samples using both manual pathologist-based
assessment and automated image analysis. Table 2 summa-
rises our findings in terms of univariate analysis of OS based
on manual and automated analysis; the table demonstrates
there is no significant difference in respect to hazard ratios
(HRs) using either manual or automated analysis in both
cohorts.
Automatic determination of the optimal threshold for 
survival analysis based on ER and PR expression
Table 2
Cox univariate regression comparing the random forest clustering (RFC) thresholds for the oestrogen receptor (ER) and the 
progesterone receptor (PR) with both the manual analysis and the 10% cutoff thresholds of the quantitative data
Manual analysis threshold 10% automated threshold RFC threshold
HR 95% CI P value HR 95% CI P value HR 95% CI P value
Cohort I (n = 179)
ER
OS 0.259 0.127 to 0.530 0.001 0.154 0.067 to 0.355 0.002 0.235 0.116 to 0.473 0.001
PR
OS 0.307 0.158 to 0.597 0.001 0.361 0.183 to 0.712 0.01 0.386 0.197 to 0.756 0.02
Cohort II (n = 564)
ER
OS 0.62 0.465 to 0.826 0.006 0.68 0.509 to 0.907 0.009 0.631 0.480 to 0.830 0.001
BCSS 0.677 0.494 to 0.928 0.006 0.664 0.492 to 0.898 0.008 0.592 0.445 to 0.787 < 0.001
RFS 0.714 0.540 to 0.943 0.009 0.797 0.603 to 1.054 0.11 0.701 0.538 to 0.914 0.009
PR
OS 0.647 0.483 to 0.867 0.004 0.719 0.538 to 0.961 0.026 0.705 0.524 to 0.947 0.020
BCSS 0.602 0.445 to 0.814 0.001 0.7 0.518 to 0.947 0.020 0.673 0.495 to 0.916 0.012
RFS 0.73 0.549 to 0.972 0.03 0.797 0.603 to 1.053 0.790 0.791 0.593 to 1.054 0.109
HR, hazard ratio; CI, confidence interval; OS, overall survival; BCSS, breast cancer-specific survival; RFS, recurrence-free survival.Breast Cancer Research    Vol 10 No 5    Rexhepaj et al.
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Based on these findings we proceeded to use random forest
clustering (RFC) in an attempt to identify new prognostic sub-
groups following quantitative assessment of the ER and the
PR. RFC is an unsupervised strategy that has been used to
profile tumours based on TMA data [12,13] and has been pre-
viously used by our group to identify new prognostic sub-
groups based on automated analysis of IHC data [10]. To this
end, Cohort I was used as a training set and Cohort II was
used as a validation set.
RFC was performed on the continuous ER and PR expression
values as determined by image analysis. This procedure
revealed two distinct clusters for ER and PR data in both
cohorts (Figure 2a to 2d). RFC performed on Cohort I revealed
an ER-negative cluster (n = 24) and an ER-positive cluster (n
= 152); similar results were seen for the PR (Figure 2a, b). In
Cohort II, the ER-negative cluster (n = 158) consisted of a
group of patients with low levels of ER expression (mean =
3%, standard error of the mean = 0.1%), while patients within
the ER-positive cluster (n = 287) had high levels of ER expres-
sion (mean = 51%, standard error of the mean = 2%) (Figure
2c, d). Likewise for the PR, the negative cluster (n = 171) con-
sisted of a group of patients with low levels of PR expression
(mean = 1%, standard error of the mean = 0.1%) and the
positive cluster (n = 253) had high levels of PR expression
(mean = 53%, standard error of the mean = 1%).
These data were, therefore, dichotomised based on the distri-
Figure 2
Threshold identification and validation for oestrogen receptor and progesterone receptor data, and marker heterogeneity assessment Threshold identification and validation for oestrogen receptor and progesterone receptor data, and marker heterogeneity assessment. 
Random forest clustering (RFC) clusters generated using automated quantitative oestrogen receptor (ER) and progesterone receptor (PR) data in 
Cohort I (test set): negative cluster and positive cluster for (a) the ER and (b) the PR. (c) ER RFC and (d) PR RFC in Cohort II (validation cohort). 
(e) Scatter plot demonstrating strong correlation between duplicate ER cores, indicating a homogenous pattern of expression. (f) Scatter plot show-
ing weaker correlation between duplicate PR cores, indicating a more heterogeneous pattern of expression.Available online http://breast-cancer-research.com/content/10/5/R89
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bution of the ER and the PR within each cluster, using a
threshold of 7% for the ER and of 5% for the PR to identify
individual clusters. The OS and RFS were examined in both
cohorts based on the thresholds identified following RFC anal-
ysis. Based on these thresholds, 9% (n = 2) of manually
assessed ER-negative tumours would be classified as ER-
positive in Cohort I and 11% (n = 15) of manually assessed
ER-negative tumours would be classified as ER-positive in
Cohort II. In Cohort I, the threshold as determined by RFC for
the ER was associated with a similar HR for OS to that of the
manual analysis and a 10% automated threshold. In Cohort II,
however, RFC clusters were associated with a lower HR as
compared with the 10% cutoff level based on automated or
manual analysis for OS, RFS and BCSS (Table 2). A 5% cutoff
threshold for the PR was associated with similar HRs to man-
ual analysis; however, an automated 10% threshold as deter-
mined by image analysis was not associated with a significant
outcome. The manually assessed ER and PR status in Cohort
II was then compared with the RFC data, and revealed 13
patients (3%) who would not receive tamoxifen based on cur-
rent manual analysis.
To investigate the true prognostic potential of a 7% cut-off for
the ER and a 5% cut-off for the PR, we analysed RFS in the
untreated arm of Cohort II. This analysis revealed that manual
analysis using a 10% cutoff level was associated with a HR of
0.64 (95% confidence interval = 0.46 to 0.81, P < 0.001);
however, a 7% threshold as determined following RFC was
associated with a lower HR and narrower confidence intervals
(HR = 0.59, 95% confidence interval = 0.44 to 0.77, P <
0.001). This would suggest that a 7% cutoff threshold may
potentially be a stronger prognostic indicator in premenopau-
sal women. The 5% cutoff level for the PR was not associated
with an improved HR as compared with manual analysis,
which could be attributed to the heterogeneous expression
pattern of this protein (discussed below).
Automated analysis of ER and PR expression and 
predicting tamoxifen response
Having demonstrated the prognostic benefit of a 7% threshold
for the ER in the untreated arm of Cohort I, we proceeded to
use the treated arm to investigate any relationship to tamoxifen
response. This investigation revealed a similar effect of 2 years
of tamoxifen treatment on the ER-positive and PR-positive
cohort of patients as determined by RFC, compared with man-
ual analysis. As expected, no treatment effect was evident in
ER-negative patients or PR-negative patients as determined
by RFC (data not shown). The effect of tamoxifen treatment
was also examined using Cox regression analysis, which
revealed that a 7% cutoff threshold for the ER was associated
with improved RFS (HR 0.579, 95% confidence interval =
0.384 to 0.872, P = 0.009) compared with the manual or
automated 10% thresholds. A similar effect was not evident
for the PR (Table 3).
ER and PR core heterogeneity
To identify the reasons underlying our different results for the
ER and for the PR, we compared the pattern of expression of
both markers in the duplicate cores. TMAs are often criticised
due to their apparent inability to account for tumour heteroge-
neity, which can partially be overcome by increased sampling.
Automated analysis allows for a systematic evaluation of
tumour heterogeneity between individual cores.
To assess the level of intra-tumour heterogeneity of ER and PR
expression as defined by image analysis, we analysed the lin-
ear relationship between ER and PR duplicate cores (Figure
2e, f). By examining the linear relationship between ER (n =
639) and PR (n = 622) duplicate cores in both cohorts, higher
linear regression coefficients were seen for the ER (R  =
0.860) than for the PR (R = 0.681). This observation would
suggest that duplicate cores from the same tumour have sim-
ilar levels of ER expression as determined by image analysis,
thus indicating the homogeneous nature of ER staining, whilst
PR expression would be associated with a more heterogene-
ous pattern of expression. It should be noted that this does not
indicate that TMA-based analysis of PR expression is not valid,
and an excellent correlation between automated and manual
assessment of PR expression was evident in this study
(described above).
Discussion
The purpose of the present study was to develop an unsuper-
vised algorithm for automated quantification of IHC-deter-
mined nuclear protein expression in breast tumour specimens.
In the current article we present data on the automated quan-
tification of the ER and the PR in 743 primary breast tumours
using such an algorithm. Our approach differs from other com-
mercially available packages in that it does not require prior
data for training purposes, and it uses a novel, fully automated
approach to isolate tumour cells from stromal tissue and lym-
phocytic infiltrate. A good counterstain is helpful; however, it
does not have to be specifically controlled for automated anal-
ysis. Heterogeneity in respect to counterstaining is handled in
our approach by using a particular colour space (CIE Lumi-
nance U-chromatic component 1 V-chromatic component 2)
combined with different morphological image operations.
Such an approach allows for the identification of negative
tumour nuclei from stromal elements, thus allowing for a more
precise determination of protein expression. The accuracy of
this approach was evident from the excellent correlation seen
between automated quantification and manual analysis (Figure
1).
The first attempts to use automated methods to quantify pro-
tein expression, as assessed by IHC, were undertaken almost
two decades ago [14,15]. Until recently, however, the image
quality and analysis software did not permit high-throughput
automated assessment of histological slides. A number of
groups have now published data on the automated assess-Breast Cancer Research    Vol 10 No 5    Rexhepaj et al.
Page 8 of 10
(page number not for citation purposes)
ment of the ER and the PR in breast cancer [16-18]. In gen-
eral, these studies are in agreement with the data presented in
the current study in relation to describing an excellent correla-
tion between manual and automated analysis. The studies by
Turbin and colleagues and by Gokhale and colleagues
describe commercially available algorithms that require spe-
cific input and training by a pathologist [16,17]. The algorithm
described in the current study differs from these approaches
in that it is entirely unsupervised and does not require any a pri-
ori data. Other approaches to the quantification of the ER and
the PR described in the literature have used antibody-conju-
gated fluorophores and fluorescent microscopy systems
[19,20]. This method, however, requires users to perform spe-
cific and complex staining protocols, which may not be suita-
ble for a busy diagnostic service.
There has been much discussion in the literature regarding the
optimal thresholds for the ER and/or the PR when identifying
patients who will benefit from anti-endocrine therapy [20-23].
Currently, a threshold of 10% positive cells is commonly used
to predict a patient's response to adjuvant hormonal therapy.
Such a cutoff threshold can lead to significant intra-observer
variability. One of the aims of the present study was to attempt
to validate currently used thresholds for the ER and the PR, as
well as to find new thresholds, using an unsupervised cluster-
ing approach. To this end, we were able to utilise a cohort of
patients who had participated in a prospective randomised
control trial comparing tamoxifen treatment with no adjuvant
treatment [2]. The untreated arm of the trial was used to eval-
uate the prognostic value of new cutoff thresholds, while the
treated arm was used to evaluate the predictive power of such
thresholds.
RFC, an approach that has been used previously by our group
[10], was utilised to identify new thresholds for survival analy-
sis. This approach identified optimal thresholds of 7% for the
ER and 5% for the PR. Interestingly, the 7% threshold for the
ER was associated with a similar outcome in Cohort I and an
improved outcome when compared with a manual 10% cutoff
level in Cohort II (Table 2). This effect was not evident for the
PR.
The true prognostic power of a 7% threshold was investigated
in the untreated arm of Cohort II, and this confirmed our find-
ings regarding both markers – specifically, ER manual analysis
using a 10% cutoff threshold was associated with a HR of
0.64 (95% confidence interval = 0.46 to 0.81, P < 0.001). A
7% threshold as determined following RFC, however, was
associated with a lower HR and narrower confidence intervals
(HR = 0.59, 95% confidence interval = 0.44 to 0.77, P <
0.001), Finally, we examined the ability of our clusters to pre-
dict the tamoxifen response in a premenopausal cohort from a
randomised control trial. This demonstrated that the RFC-
based approach was associated with better outcomes, indi-
cating that this approach would be a more accurate predictor
of tamoxifen response (Table 3). This observation suggests
that 10% is a suboptimal threshold for the ER when predicting
the tamoxifen response. What should also be acknowledged,
however, is that a 7% cutoff threshold for manual analysis is
perhaps not feasible and would lead to an increase in both
intra-observer and inter-observer variability.
These data also confirm previously published findings describ-
ing the heterogeneous pattern of expression for the PR [20].
One of the arguments against TMA-based approaches is that
they do not give a true representation of proteins that display
such heterogeneity in expression terms [24,25]. In the present
study we have used an image analysis approach to address
marker heterogeneity. If TMAs are to be used for high-through-
put biomarker validation in the future, an ability to identify pro-
teins exhibiting such varied expression patterns would be
extremely helpful and avoid the reporting of potentially biased
data. The method would also allow investigators to proceed, in
a systematic manner, onto full-face sections at an earlier stage
in the validation process. Our approach revealed that the ER
displayed a much more homogeneous pattern of expression
than the PR (Figure 1g, h). Our data are in agreement with
other studies. For example, in a review of 5,993 cases, Nadji
and colleagues demonstrated that the ER displayed a homo-
geneous pattern of expression in 92% of cases, whilst the PR
displayed a heterogeneous pattern of expression in 21% of
cases [26]. We believe this observation may indicate why our
results for the PR were not as consistent as those seen for the
Table 3
Cox univariate regression of recurrence-free survival in the treated arm of Cohort II
Cohort II treated arm (n = 276)
Oestrogen receptor Progesterone receptor
HR 95% CI P value HR 95% CI P value
Manual analysis 0.622 0.413 to 0.936 0.023 0.566 0.368 to 0.869 0.009
Automated 10% threshold 0.666 0.434 to 1.022 0.063 0.64 0.534 to 0.955 0.04
Automated clustering 0.579 0.384 to 0.872 0.009 0.67 0.431 to 1.043 0.07
HR, hazard ratio; CI, confidence interval.Available online http://breast-cancer-research.com/content/10/5/R89
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ER; however, this does not preclude TMA-based analysis of
PR expression.
Conclusions
We have successfully developed and validated a novel
approach to quantify nuclear protein expression in breast
tumours using image analysis of IHC data. Moreover, we have
validated 7% as the optimal cutoff threshold for the ER, by uti-
lising two independent cohorts comprising a total of over 700
patients. Our data would also suggest that image analysis
approaches may provide more sensitive measures of predict-
ing tamoxifen response, whereby a 7% cutoff threshold pre-
dicts improved response to tamoxifen. Based on our findings
in the present study, 13 patients (3%) who would not currently
receive tamoxifen would have benefited from the drug. One
potential weakness of the current study is that it was based on
a TMA platform. Therefore, it is planned to proceed to apply
this technology to full-face sections derived from breast biop-
sies and resections. This would allow the algorithm to be uti-
lised in routine pathological practice.
There is an urgent need for new prognostic and predictive
assays that would allow for improved patient stratification in
breast cancer. Whilst a huge emphasis has been placed on
DNA microarrays as the basis of such new tests [27], it is now
becoming obvious that IHC surrogates may be a more appro-
priate clinical assay than gene expression-based platforms in
the future [28]. As demonstrated by Nielsen and colleagues
and by Careyand colleagues, it is possible to identify molecu-
lar subgroups (luminal A, luminal B, basal and Her2) using a
small number of IHC markers [29,30]. Likewise, Ring and col-
leagues have reported on a novel panel of five antibodies that
can predict outcome in ER-positive tumours [31]. More
recently, Crabb and colleagues described a novel eight-
marker, IHC-based, prognostic test for patients with advanced
lymph-node-positive (>4 positive lymph nodes) disease [32].
These findings combined with large-scale antibody-based-
proteomics resources, such as the Human Protein Atlas pro-
gramme [33], will most probably lead to an increased use of
multiplex IHC assays as both predictive and prognostic tests.
The use of automated algorithms such as the one described in
the present paper can only help to advance this process,
whilst the use of novel approaches such as RFC may lead to
the identification of new prognostic and predictive subgroups,
allowing for tailored treatment regimens for individual patients
– also known as personalised medicine.
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